Exploration of anticancer potential of hydroxamate derivatives as selective HDAC8 inhibitors using integrated structure and ligand based molecular modeling approach by Rajak, Harish  et al.
Indian Journal of Chemistry 
Vol. 60B, January 2021, pp. 136-147 
Exploration of anticancer potential of hydroxamate derivatives as selective HDAC8 
inhibitors using integrated structure and ligand based molecular modeling approach 
Ekta Shirbhatea, Divyaa, Preeti Patela, Vijay K Patela, Ravichandran Veerasamyb & Harish Rajak*a 
a Medicinal Chemistry Research Laboratory, Institute of Pharmaceutical Sciences, 
Guru Ghasidas University, Bilaspur 495 009, India 
b Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia 
E-mail: harishdops@yahoo.co.in
Received 17 January 2020; accepted (revised) 11 November 2020 
Recently, histone deacetylase inhibitors are evolving as an exhilarating new class of promising antitumor agents for the 
treatment of multiple malignancies. It may play a pivotal role as a therapeutic target for challenging the globally wide spread 
disease, cancer. At the same time, the prediction of biological activity of novel compounds, which was once a major 
challenge in drug design, is also pacing up its speed. This computational study has been performed in Schrodinger suite 
packages such as sitemap generation, grid formation, Glide for docking, Quikprop for ADME analysis, e-pharmacophore 
post docking script and Phase for 3D QSAR models designing, that all are available in Maestro version 9.3. Docking not 
only helps in predicting the preferred orientation of ligand with its target receptor, but also the binding affinity between the 
ligand and receptor. The application of Phase and e-pharmacophore script predicts some computational models of the 
provided ligands using 3D QSAR method. This decreases the cost and time of biological experiments. Glide XP reveals that 
compound 21 with the highest score value as the best compound from the dataset. Also, it shows good R2=0.9834,  
Q2= 0.7753, stability = 0.5407 and low standard of deviation SD=0.1085 for hypothesis ADDRR.1601, for the PLS factor 5. 
The outcome of these studies suggests compound 21 as a potential drug molecule for HDAC targets. 
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Cancer is now a serious disease that endangers human 
health. It is the second prominent root of death globally 
and is appraised to interpret for 9.6 million deaths in 
2018 (as per WHO report). Lung, prostrate, colorectal, 
stomach and liver cancer are recorded common types 
of cancer in men, though breast, colorectal, lung, cervix 
and thyroid cancer are the most common amongst 
women. In recent years, number of studies have shown 
that HDAC inhibitory drugs could inhibit the growth of 
tumors. There are many HDAC inhibitory drugs 
undergoing long research and development cycle1-3. 
The steady process of histone acetylation is balanced 
by histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). HATs makes the addition of 
acetyl groups to lysine residues of histone tails causing 
relaxation of chromatin and activation of transcription 
of nearby genes. On the contrast, HDACs remove the 
acetyl groups of acetylated histones leading to 
transcriptional suppression. HDAC therefore plays an 
important role in upregulating gene transcription, 
cell cycle progression and apoptosis. HDACs hence 
can be considered as a promising targets for 
cancer therapy4. 
Till now, 18 mammalian HDACs have been 
identified and studied, which were divided into five 
groups: class I (HDAC1, 2, 3 and 8), class II which 
was further sub divided into class IIa (HDAC 4, 5, 7 
and 9) and class IIb (HDAC 6 and 10), class III (SIRT 
1 to 7) and finally class IV (HDAC 11)5-7. The 
enzymes of classes I, II and IV are Zn2+ dependent 
metallohydrolases5,7. Class I enzymes are principally 
confined to the nucleus and are responsible for cell 
proliferation and differentiation5,8. Class III enzymes 
are NAD2+ dependent Sir2-like deacetylases5,7. 
Mainly, this class I and IIb are found to be over 
expressed in most hematological and solid tumors, 
extremely associating with a shoddier prognosis. 
Consequently, class I and IIb target selective 
inhibitory agents turn out to be a key attention in 
cancer chemotherapy5. HDAC inhibitors are mainly 
recorded into few classes of hydroxamates, 
benzamides, aliphatic acids, cyclic tetra peptides, 
electrophilic ketones and some other types, suitably 
mentioned in table (Table I). This classification was 
based according to their chemical structures. At present, 
five HDAC inhibitors have been approved by FDA, 




which plays a significant role in the treatment of various 
melanomas, again mentioned in (Table I). These all 
HDAC inhibitory drugs share a similar pharmacophore 
skeleton consisting of following four key binding 
components: zinc binding group (ZBG), linker, 
connecting unit and cap moiety. Structural modification 
of HDAC inhibitors are mainly focused on the cap and 
linker realms to optimize activity and selectivity9. 
As it is evident, the process of drug discovery and 
development is very challenging, puzzling, expensive 
and time consuming. But gradually it has been 
accelerated due to the incorporation of computational 
tools and methods in this field. Over the last decade, 
the CADD (computer aided drug design), also known 
as in silico screening has come to be a prevailing 
technique in drug discovery and design, as it covers a 
wide range of computational approaches and new 
methodologies. It possesses combination of various 
advanced features enabling it to construct track for the 
synthesis and screening of designated compounds for 
improved therapeutics. In silico drug designing 
includes various steps like molecular docking, 
homology modelling, multi target searching  
and designing, pharmacophore development, 
conformation generation and quantitative structure 
activity relationship (QSAR)10. 
Table I — List of FDA approved HDAC inhibitors 
Sr. 
No. 
Class List of 
HDAC 
inhibitors 







1 hydroxamate Vorinostat 
(SAHA) 
 
2006 US-FDA Pan cutaneous  
T-cell 
lymphoma 
2 hydroxamate Belinostat 
(PXD-101) 
 
2014 US-FDA Pan peripheral  
T-cell 
lymphoma 
3 hydroxamate Panabiostat 
(LBH-589) 
 
2015 US-FDA Pan peripheral T-
cell 
lymphoma 
4 cyclic peptide Romidepsin 
(FK228) 
 
2009 US-FDA selective 
inhibits Class 




5 benzamide Chidamide 
 
2014 CFDA selective 
inhibits Class 








Result and Discussion 
Molecular docking study 
The results of molecular XP docking highlight 
apparent binding efficiency of hydroxamic acid based 
molecules with receptor protein 1T69 (Figure 1a). The 
compound 21 from the dataset showed maximum 
structural alignment with that of SAHA in protein 1T69. 
The interactions were metal coordination, hydrogen 
bonding (backbone and side chain), hydrophobic 
interaction, hydrophilic interaction and pi-pi stacking. 
The 2D interaction diagram (Figure 1b) of compound  
21 docked with protein showed metallic bond interaction 
between keto group of molecule with Zinc (Zn378) of 
receptor 1T69. The 2D interaction diagram displayed 
hydrophobic interaction between PHE207 amino acid 
with five membered triazole ring, and PHE208 with 
terminal benzene ring. It displayed hydrophilic 
interaction of amino acid HIE180 with triazole moiety 
and HIS143 with triazole attached benzene ring of 
phenylhydroxylamine. Also, hydrogen bonding was 
noticeable at multiple positions: PHE152 and  
NH- group of hydroxamic acid scaffold, GLY206 and 
hydroxyl group of cap, TYR306 and keto group of 
connecting unit and finally between GLY151 and  
NH- moiety of connecting unit. 
ADMET analysis 
It utilizes the physicochemical parameters to 
explain the vital properties affecting the biological 
functions. Permeability, solubility, lipophilicity, 
integrity, stability, etc. are some important measurable 
physicochemical properties. Though the concept of 
ADME has now been extended to toxicity. Right from 
the starting of drug discovery, the in silico method is 
helpful in predicting pharmacokinetic properties for 
instant ADMET. Among the dataset of 38 
compounds, 10 compounds were filtered through 
Quikprop feature (Table II). 
 
Energetic (e)- Pharmacophore study 
The result of e-pharmacophore hypothesis study 
displayed hypothesis for compound 21 with protein 
1T69. As default, maximum of seven pharmacophoric 
features were adopted. The generated hypothesis 
represented one hydrogen bond acceptor, three 
hydrogen bond donors, two aromatic rings and one 
hydrophobic/ non polar group (Figure 2a). Its ranking 
order and scoring value specify that the aromatic 
rings, R14 and R15 creates hydrophobic environment. 
The acceptor, A6 and donor, D8, D9 and D10 
participates in hydrogen bonding. Ultimately,  
non-polar group, H12 involved in hydrophobic 
enclosure interaction. (Table III) 
 
Pharmacophore modelling 
The result for pharmacophore and atom centered 
3D QSAR modelling was attained from “Phase” v3.4 
feature of Maestro. The best 10 hypotheses were 
selected (Table IV) and thereby on relating the 
survival score of all the spawned hypotheses, it 
directed that pharmacophore model generated by 
hypothesis ADDRR.1601 has the preeminent survival 
score (Figure 2b). It disclosed the best alignment over 
most active molecule accompanying distance (Å). The 
ligand based pharmacophoric model, ADDRR.1601 
unveiled five significant features counting one 
hydrogen bond acceptor, two hydrogen bond donors 
and two aromatic rings showing highest survival score 
value of 3.178. 
 
3D-QSAR Modelling 
The prime aim of developing 3D-QSAR model is to 
facilitate a mathematical relationship between the 3D 
spatial layout of the pharmacophoric features with the 




Figure 1 — Docking pose of compound 21 complexing with 1T69
protein (a) Docking pose alignment showing crystal ligand SAHA
(green) and docked ligand (grey) (b) 2D interaction pattern of
ligand with protein 





data set of 38 compounds were distributed into active, 
moderately active and inactive array, based on 
assumed activity threshold (6.80-5.80). A total of  
38 molecules were additionally partitioned into 
training set (27) and test set (11). Five featured 
containing CPH (ADDRR.1601) was selected for 
atom-based 3D QSAR model development, 
considering PLS factor as 5. The CPH ADDRR.1601 
executed best statistical conclusion for PLS factor 5 
revealing Q2 (0.7753), R2 (0.9834), SD (0.1085),  
F (261), P (8.185e-019), RMSE (0.265), stability 
(0.5407) and Pearson-R (0.7478) (Table V). The 
predicted activities of training and test set, along with 
their fitness value for CPH ADDRR.1601 is 
represented in Table IV. The residual values were 
computed by reduction of predicted activity from 
observed activity. The sum of residual value was 
computed as -0.1684 for model generated from 
hypothesis ADDRR.1601 (Table VI). Scatter plots of 
actual vs. predicted activity for both training and test  
Table II — Analysis of physicochemical properties and biological functions of filtered molecules from the  


























(4.0 to 45.0) 
Human oral 
absorption  
(1, 2, 3 for low, 
medium, high) 
CNS (-2 for 
inactive, +2 
for active) 





1 466.499 1532.17 885.656 12.95 3 12 22.182 1 -2 1 
3 546.544 1732.322 1000.43 16.2 4 17 28.437 1 -2 2 
8 559.586 1800.025 1028.035 16.2 4 17 27.954 1 -2 1 
9 440.464 1451.384 839.528 13.7 3 11 22.741 1 -2 1 
12 533.368 1441.492 839.461 8.7 3 17 18.947 2 -2 1 
21 530.42 1569.961 902.493 10.9 4 17 22.04 2 -2 1 
25 530.42 1570.055 902.637 10.9 4 17 22.037 2 -2 1 
29 530.42 1553.052 880.96 10.4 4 17 21.42 2 -2 1 
33 530.42 1548.908 882.869 10.4 4 17 21.414 2 -2 1 
38 466.499 1553.764 908.892 12.95 3 12 22.483 1 -2 1 




Figure 2 — Pharmacophore hypothesis. Pharmacophore features
elucidating hydrogen bond acceptor (A, pink), hydrogen bond
donor (D, blue) and aromatic rings (R, brown) (a) Pharmacophore
model ADDDHRR developed using the e-pharmacophore script
(ligand and structure based approaches)(b)Pharmacophore model
AADRR.1601, developed using the Phase module (ligand based
approach) 
Table III — Score of pharmacophoric features based on energetic 
terms of XP docking 
Rank Feature label Score  
(kcal / mol) 
Score source 
1 R14 -1.89 Ring ChemscoreHPhobe 
2 D8 -0.59 H Bond 
3 D9 -0.59 H Bond 
4 D10 -0.59 H Bond 
5 H12 -0.55 PhobEn + none 
6 A6 -0.35 H Bond 
7 R15 -0.62 Ring ChemscoreHPhobe 





Table IV — Hypothesis Score generated by Phase 
Sr. No. Hypothesis Survival Survival-inactive Post-hoc Site Vector Volume Matches 
1 ADDRR.1601 3.282 1.06 3.282 0.75 0.956 0.573 5 
2 AADDR.2385 3.237 1.166 3.237 0.76 0.952 0.516 5 
3 AAAHR.301 3.178 1.52 3.178 0.652 0.878 0.652 5 
4 ADDHR.2499 3.352 1.856 3.352 0.75 0.912 0.665 5 
5 AAHRR.1891 3.145 1.336 3.145 0.67 0.875 0.6 5 
6 AADHR.1245 3.35 1.3 3.35 0.76 0.989 0.596 5 
7 ADHRR.127 3.228 1.855 3.228 0.66 0.93 0.643 5 
8 DDHRR.217 3.333 1.628 3.333 0.72 0.942 0.668 5 
9 AAAHR.2654 3.339 2.093 3.339 0.67 0.958 0.706 5 
10 AADDH.6219 3.347 1.926 3.347 0.82 0.93 0.598 5 
 
Table V — Statistical result of the developed 3D QSAR model using ADDRR.1601 CPH 
ID PLS fact. SD R2 F P Stability RMSE Q2 Pearson-R 
 
ADDRR.1601 
1 0.3674 0.7756 89.9 6.375e-010 0.8254 0.3432 0.6292 0.7652 
2 0.2169 0.9248 153.6 9.034e-015 0.6855 0.2836 0.7446 0.8201 
3 0.1473 0.9667 232.2 7.397e-018 0.5863 0.3003 0.6964 0.8585 
4 0.1270 0.9763 236.7 2.509e-018 0.5662 0.2825 0.7300 0.8632 
5 0.1085 0.9834 261 8.185e-019 0.5407 0.2650 0.7753 0.8779 
 
Table VI — Comparison between experimental and predicted activity along with fitness values of dataset ligands,  
which are obtained from the best generated atombase3D-QSAR models ADDRR.1601 
Lig. Name QSAR set Experimental activity Predicted activity Residual Fitness Pharma Set 
3D QSAR ADDRR.1601 
1 training 5.134 5.10 0.034 2.54 Inactive 
2 test 6.151 6.12 0.031 1.88 + 
3 test 6.186 6.01 0.176 1.34 + 
4 training 7.119 7.18 -0.061 2.80 Active 
5 training 7.086 7.12 -0.034 2.26 Active 
6 training 7.553 7.49 0.063 2.22 Active 
7 training 6.833 6.85 -0.017 1.94 Active 
8 training 6.321 6.35 -0.029 2.35 + 
9 training 7.770 7.81 -0.04 1.84 Active 
10 training 5.556 5.24 0.316 2.01 Inactive 
11 training 4.921 5.04 -0.119 2.00 Inactive 
12 training 4.523 4.85 -0.327 2.00 Inactive 
13 training 5.282 5.26 0.022 1.86 Inactive 
14 training 5.879 5.92 -0.041 1.79 Inactive 
15 test 5.924 5.78 0.144 2.86 + 
16 training 5.379 5.37 0.009 1.81 Inactive 
17 training 5.561 5.52 0.041 2.03 Inactive 
18 test 5.401 5.80 -0.399 1.64 Inactive 
19 training 6.099 6.11 -0.011 1.64 + 
20 test 5.706 5.77 -0.064 1.57 Inactive 
21 training 5.504 5.50 0.004 3.00 Inactive 
22 test 5.701 6.13 -0.429 2.81 Inactive 
23 training 6.258 6.33 -0.072 1.80 + 
24 training 5.556 5.55 0.006 1.99 Inactive 
25 training 6.357 6.37 -0.013 1.92 + 
26 training 6.102 6.06 0.042 2.60 + 
      (contd.)




Table VI — Comparison between experimental and predicted activity along with fitness values of dataset ligands,  
which are obtained from the best generated atombase3D-QSAR models ADDRR.1601  (contd.) 
Lig. Name QSAR set Experimental activity Predicted activity Residual Fitness Pharma Set 
   3D QSAR ADDRR.1601  
27 training 5.697 5.65 0.047 1.62 Inactive 
28 test 6.286 6.01 0.276 1.97 + 
29 training 6.133 6.09 0.043 1.58 + 
30 test 6.634 6.37 0.264 2.06 + 
31 training 6.277 6.27 0.007 1.94 + 
32 training 6.026 5.95 0.076 1.92 + 
33 test 6.391 6.04 0.351 1.73 + 
34 test 5.745 5.90 -0.155 1.54 Inactive 
35 training 5.398 5.36 0.038 0.87 Inactive 
36 training 5.721 5.74 -0.019 1.53 Inactive 
37 training 5.567 5.54 0.027 1.85 Inactive 
38 test 5.134 5.52 -0.386 0.32 Inactive 
+ Represents moderately active compounds. 
 
set molecules were contrived (Figure 3). It could be 
used to sketch the actuality of QSAR model. 
 
Model visualization 
The 3D QSAR models were established for the 
dataset of compounds using common pharmacophore 
hypothesis ADDRR.1601, for validation purpose. An 
expressive demonstration of the cubes produced in 3D 
QSAR model (Figure 4), illuminating features like 
hydrogen bond donor, hydrophobic / non-polarity and 
electron withdrawing nature. The pink colored cubes 
reveal favorable condition, while the yellow cubes 
showing unfavorable condition for biological activity. 
The ligand 4 from the dataset which was more 
specifically from the training set was selected as the 
template molecule for building model with CPH 
ADDRR.1601. It enables much better understanding 
of the study. 
The replacement of H attached with nitrogen atom 
of hydroxamate moiety with hydrogen donating group 
shows an increase in activity, however in contrary, 
hydroxyl group of this hydroxamate moiety when 
replaced by H donating groups exhibit antagonistic 
effect and hence it may be replaced with some other 
H-bond acceptors for an improvement in activity. 
Also the methylene attached directly with ZBG 
showing favorable nature for activity, displaying that 
on increasing unsaturation at this position may lead to 
decrement or loss in activity. The model also reveals any 
kind of substitution of hydrophobic group at various 
positions on benzene ring is helpful for activity. 
Similarly, replacing H of methylene group that is present 




Figure 3 — Training (a) and test (b): Plots showing observed 
activity versus predicted activity, for 3D QSAR models generated 
using ADDRR.1601 





would favour for activity and oxygen of hydroxyl part of 
ZBG would decrease its activity. In addition, 
substitution of electron withdrawing group in pyrazole 
ring and ortho and meta position of benzene ring leads 
to rise and fall in activity, respectively. Also, again it 
shows that on replacing H of methylene moiety adjacent 
to ZBG may result in decrement in activity. 
The conclusion of this computational task evidently 
reveal that compound 21 is achieving many traits of 
high docking score, good ADME properties with 
lower toxicity, highest fitness value, better drug 
physicochemical properties and desirable 
conformation than the original ligand. Hence it can be 
considered as a potential lead molecule. 
 
Material and methods 
This computational tasks like protein preparation, 
ligand preparation, grid development, Glide  
XP molecular docking, ADME analysis,  
e-pharmacophore script generation and 3D QSAR 
model designing were performed out by employing 
various features of Schrodinger suite (Maestro version 
9.3) LLC, New York software11. 
 
Dataset preparation 
The dataset of 38 compounds possessing 
hydroxamic acid as preeminent scaffold, although 
showing wide structural variance, were selected from 
acceptable research papers for computational analysis. 
The compounds were found to exhibit same biological 
assay i.e., fluorescence assay method12. Molecular 
structures and activity information of compounds 
engaged for 3D QSAR study (Table VII). The IC50 
values were converted into negative logarithm of IC50 
(pIC50)
13. The IC50 value was used as a dependent 
variable in QSAR study. These data are important for 
observing structure activity relationship by 
establishing effective 3D QSAR models. 
Protein preparation 
The protein was endowed by the “protein 
preparation wizard” tool in Maestro v9.3 
(Schrodinger, LLC, NY). Primarily, it was essential to 
identify the binding region and binding mode of 
HDAC inhibitor, that was done by complexing crystal 
structure of SAHA with HDAC protein (PDB ID: 
1T69)14. The work was accomplished in three steps, 
(i) Import and process: drifting the protein from 
recognized database (PDB) and processing it to fix its 
structure; (ii) Review and modify: deleting unwanted 
changes and solving some protein problems such as 
missing side chain and backbone and also, updating 
the missing residues. The water molecules occupying 
target creates difficulty in docking simulation and 
hence evacuated13. (iii) Refine: optimizing the 
orientation of H-bonding groups and minimizing the 
structure by OPLS_2009 force field14,15. 
 
Ligand preparation 
The dataset of ligands were constructed and 
processed through “Lig prep” v2.5 tab in Maestro 
v9.3 (Schrodinger, LLC, NY). The molecular 
structures of these ligands were traced in Chemdraw 
Professional v16.0 and retained in mol format. The 
molecules were converted from 1D (Smiles) and 2D 
(SDF) representation to 3D structures, probed for 
tautomers and steric isomers and geometric 
minimization of ligands through OPLS_2005 force 
field. The partial atomic charges were enumerated by 
OPLS_2005 (Optimized Potential Liquid Simulation) 
force field11,16. 
 
Binding site analysis and grid generation 
The site analysis plays a pivotal role in molecular 
docking research analysis. It efficiently exposes the 
active site in the target protein welcoming the 




Figure 4 — Visualization of QSAR models generated using hypotheses ADDRR.1601 for various substituent groups (a) H-bond donor 
(b) Hydrophobic / non polar (c) Electron withdrawing. Pink cubes indicate favorable regions, whereas Yellow cubes indicates
unfavorable regions for the activity. 





Table VII — Chemical structures and pIC50 values of the selected compounds for the dataset 
Sr.No. R HDAC8 IC50 
(µM) 




































Table VII — Chemical structures and pIC50 values of the selected compounds for the dataset  (contd.) 
Sr.No. R HDAC8 IC50 
(µM) 






































      (contd.)




Table VII — Chemical structures and pIC50 values of the selected compounds for the dataset  (contd.) 
Sr.No. R HDAC8 IC50 
(µM) 













































entirely considered along the surface and interior 
regions of the target by the sitemap generation course. 
In target 1T69 protein, suberoylanilide hydroxamic 
acid (SAHA) was selected as the suitable active site 
for grid generation11. The “receptor grid generation” 
panel of Glide tab analyzes and work by fixing the 
drug target site in the target molecule. The receptor 
grid box was generated in a cubical shape having X: 
20Å; Y: 20Å; Z: 20Å coordinates. The default values 
of Vander Waals’ radii scaling factor, charge scaling 
factor and partial charge cutoff were 1.0, 1.0 and 0.25, 
respectively14. The grid generated helps to finalize the 
ligand docking method11. 
 
Molecular docking (XP Docking) 
In this research, “Glide” v5.8 (Schrodinger, LLC, 
NY), a molecular docking tool was used for docking 
studies to predict ligand efficiency, binding affinity 
and inhibitory constant towards target. The dataset of 
ligands was docked with the active of target using 
Glide extra precision approach11 providing XP 
docking score. It provides a peculiar scoring function 
in form of GScore values14 that helps in identifying 
the best possible conformer with the most favorable 
binding affinity14,17. The GScore comprises of the 
summation of XP terms obtained from hydrophobic 
grid potential and segment of the total protein ligand, 
π-π stacking, π-cation interaction, Vanderwaal energy, 
various rewards (i.e., electrostatic ligands with low 
molecular weight), various penalties (i.e., intra-ligand 
contacts, ratable bond) and other interactions. 
 
ADMET analysis 
The Quikprop tool in Maestro v9.3 provides 
information about ADMET properties of compounds. 
Some of these properties includes H-bond donor 
group, H-bond acceptor group, SASA, Blood-Brain 
Barrier (BBB), QPlogPw, human oral absorption, rule 
of five and CNS11. 
 
Energetic (e)-Pharmacophore hypothesis generation 
The e-pharmacophore hypothesis generation 
employs an integrated structure and ligand based 
method. It was performed through “docking post 
processing” option under e-pharmacophore script tab 
in Maestro v9.3 application14. The energetic values of 
XP Glide scoring function was used to map energy 
optimized pharmacophore (e-pharmacophores). 
Consequently, pharmacophore sites were created by 
employing “Phase” tool with six default chemical 
features: hydrogen bond donor (D), hydrogen bond 
acceptor (A), hydrophobic/non-polar group(H), 
negative ionisable (P), positive ionisable (N) and 
aromatic ring (R). Each pharmacophore site generated 
comprises of cumulated values of XP Glide docking 
energies of the atoms. Sites were then graded 
according to their docking energies and the most 
justified site was screened for hypothesis17. 
 
Pharmacophore modelling 
The “Phase v3.4” tool in Maestro v9.3 helps to 
develop ligand-based pharmacophore models which 
impressively guide for common pharmacophore 
identification and 3D QSAR model formation. The 
exercise was started with the cleaning of all 38 
ligands. The ligands were then subjected to conformer 
generation macromodel search method to generate 
their conformers keeping maximum number of 
conformers as 1000 per structure and these structures 
were then minimized employing OPLS_2005 force 
field using 100 minimization steps12,18,24. The sites 
generated for ligands provide different 
pharmacophore hypotheses on the basis of activity 
threshold of active and inactive molecules. Each 
pharmacophore hypothesis contains a maximum of 
six chemical features: hydrogen bond donor (D), 
hydrogen bond acceptor (A), hydrophobic/non-polar 
group(H), negative ionisable (P), positive ionisable 
(N) and aromatic ring (R). These generated 
hypotheses were graded based on their survival, 
survival inactive, post-hoc scores, vector, volume and 
site scores12,19,24. The best pharmacophore model was 
screened and identified by suitable aligning of the 
active ligand with hypothesis providing additional 
useful information for the further QSAR studies12,20. 
 
Atom based 3D QSAR modelling 
The atom based 3D QSAR model designing was 
done using best fit designated hypothesis possessing 
the good scoring value. The dataset was efficiently 
divided into training and test set for analysis. The 
distribution was done such that 80% of the molecules 
fall within the training set and the remaining 20% as 
the test set fluctuating from maximally active to 
moderate and then smallest active (on the basis of 
IC50) compounds
12,21. The activity threshold was 
assumed between 6.8 to 5.8. The grid spacing was 
maintained as 1Å and 5 as maximum PLS factor12,22. 
The model designed must show good statistics and 
predictive ability. The QSAR result was finally 








The present research work highlights the strategy 
of innovative HDAC inhibitory drugs by uniting 
diverse features of in silico methodology. The 
molecular docking (XP dock), energetic based 
pharmacophore mapping, pharmacophore and atom 
based 3D QSAR model designing and study enables 
to establish activity correlation between structure of 
dataset molecules and its biological solicitation. It 
basically employs a combination of both structure and 
ligand based approaches. The ligand based 
pharmacophore was developed using Maestro v9.3. 
The dataset was selected from the earlier research 
findings. The target and ligand molecules were 
procured from recognized databases, which were 
incorporated into pivotal findings. The docking 
studies indicated the important intermolecular 
interactions between the moieties of ligands with the 
amino acids present in target protein. The developed 
3D QSAR model expending the pharmacophore-
based orientation exhibited extraordinary standards of 
regression coefficient for training set showing  
Q2 = 0.7753 and R2 = 0.9834 with low  
RMSD = 0.1085. The present findings would pave the 
way for design and development of novel HDAC 
inhibitors as anticancer agent. 
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